Suppr超能文献

ERK1/2-Egr-1 信号通路介导电针对心肌缺血再灌注损伤小鼠的保护作用。

ERK1/2-Egr-1 Signaling Pathway-Mediated Protective Effects of Electroacupuncture in a Mouse Model of Myocardial Ischemia-Reperfusion.

机构信息

Department of Anesthesiology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, 1630 Dongfang Road, Shanghai 200127, China.

Department of General Surgery, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200062, China.

出版信息

Evid Based Complement Alternat Med. 2014;2014:253075. doi: 10.1155/2014/253075. Epub 2014 May 5.

Abstract

Early growth response- (Egr-) 1 is an upstream master switch in controlling inflammatory responses following myocardial ischemia-reperfusion (I/R). Activation of extracellular signal-regulated protein kinase-1 and kinase-2 (ERK1/2) signaling is known to upregulate Egr-1. ERK1/2 pathway has been previously shown to mediate the therapeutic action of electroacupucture (EA). Thus, we hypothesized that EA would reduce myocardial I/R injury and inflammatory responses through inhibiting Egr-1 expression via the ERK1/2 pathway. Mice were pretreated with EA, U0126, or combination of EA and U0126 and then underwent 1 h myocardial ischemia and 3 h reperfusion. We investigated that EA significantly attenuated the I/R-induced upregulation of both Egr-1 and phosporylated-ERK1/2 (p-ERK1/2), decreased myocardial inflammatory cytokines including tumor necrosis factor- α (TNF- α ) and interleukin-1 β (IL-1 β ), and reduced the infarct size and the release of cardiac troponin I (cTnI). U0126 treatment also exhibited the same effect as EA on Egr-1 level and subsequent cardioprotective effects. There was no additive effect of cotreatment with EA and U0126 on the expression of Egr-1 and its downstream target genes (TNF- α , IL-1 β ) or serum cTnI level. Collectively, these observations suggested that EA attenuates myocardial I/R injury, possibly through inhibiting the ERK1/2-Egr-1 signaling pathway and reducing the release of proinflammatory cytokines.

摘要

早期生长反应因子-1(Egr-1)是控制心肌缺血再灌注(I/R)后炎症反应的上游主开关。已知细胞外信号调节蛋白激酶-1 和激酶-2(ERK1/2)信号的激活可上调 Egr-1。ERK1/2 通路先前已被证明可介导电针(EA)的治疗作用。因此,我们假设 EA 通过 ERK1/2 通路抑制 Egr-1 表达,从而减轻心肌 I/R 损伤和炎症反应。用 EA、U0126 或 EA 和 U0126 的组合预处理小鼠,然后进行 1 小时心肌缺血和 3 小时再灌注。我们研究发现,EA 显著减弱了 I/R 诱导的 Egr-1 和磷酸化-ERK1/2(p-ERK1/2)的上调,降低了心肌炎症细胞因子,包括肿瘤坏死因子-α(TNF-α)和白细胞介素-1β(IL-1β),并减少了梗塞面积和心肌肌钙蛋白 I(cTnI)的释放。U0126 治疗对 Egr-1 水平及其随后的心脏保护作用也表现出与 EA 相同的效果。EA 和 U0126 联合治疗对 Egr-1 及其下游靶基因(TNF-α、IL-1β)的表达或血清 cTnI 水平没有相加作用。综上所述,这些观察结果表明,EA 通过抑制 ERK1/2-Egr-1 信号通路和减少促炎细胞因子的释放来减轻心肌 I/R 损伤。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3290/4026842/fdd0bc60bbe5/ECAM2014-253075.001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验